ERBB2 and neoplasm: This study revealed that the DVPC trend in HER2‐low tumors was initially positive and then negative, indicating that, during contrast agent infusion to the peak, the signal enhancement within the tumor was greater than that in the reference area; after reaching the peak, the contrast agent rapidly declined.